C71T
CANCELLED SECTION 71
31/07/2026
Voltar para busca
Dado oficial do USPTO
BRIGHTPLEX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
BRIGHTPLEX
ST13
US500000079260990Classe
5, 9, 42, 44
Pedido
79260990
Registro
5958367
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
31/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 9, 42, 44
Data de depósito
18/04/2019
Data de registro
14/01/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
31/07/2026
Última transação
31/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
34
Localização do titular
FR
Examinador
PENDLETON, CAROLYN A
Unidade examinadora
L30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Veracyte
HalioDx
Representantes
Timothy Dell Nichols Workman Nydegger
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for use in in vitro testingfor use in the clinical diagnosisprognosismonitoringprediction of response to treatments and on-going evaluationanalysis and study of a cancertumor or equivalent medical condition; chemical preparations for medical and pharmaceutical use for use in in vitro testingfor use in the clinical diagnosisprognosismonitoringprediction of response to treatments and on-going evaluationanalysis and study of a cancertumor or equivalent medical condition; biological reagents for medical use for providing diagnostic or identification information of biological systems; immunological reagents for medical use; biological reagents for medical diagnosis; medical diagnostic kits comprising biological markersreagents and medical tests for diagnostic purposesfor testing biological tissue samples; biological reagents for medical research; biological reagents for medical use; biological reagents for clinical diagnosis
Classe 9
Recorded software for use in the clinical diagnosisprognosismonitoringprediction of response to treatment and on-going evaluationanalysis and study of a cancertumor or equivalent medical condition
Classe 42
Researchdevelopmenttechnical design and scientific testing services in the field of oncology; industrial analysis and research services in the field of oncology; clinical trial services for others; tests in laboratoriesanalysis of biological mechanisms of actionsbiomarkers and signatures for research in biology purposes; development of quality control testing methods for others; researchdevelopmenttechnical designtestingconsulting and analysis services in the field of immunology and oncology; research and development of antibodiestherapeutic productsvaccinesimmunotherapy treatments and diagnostic products; research services in the field of immune repertoire analysis and the genome; design and development of software in the field of biology
Classe 44
Medical analysis servicesanalysis of tumorcancer or equivalent medical condition; medical assistance; health care services; medical therapeutic services; medical diagnosticsdiagnostics in the field of medicine; genetic and tissue analysis services for medical purposes; medical testing services for the detectionquantificationlocalization of proteins or cells on a section of biological tissue for the purposes of medical diagnosisanalyzing the immune contexture of a tumor
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
21/08/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
14/01/2025
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
12/02/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
22/05/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
24/04/2020
FIMP
FINAL DISPOSITION PROCESSED
24/04/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
14/04/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
14/01/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
29/10/2019
PUBO
PUBLISHED FOR OPPOSITION
29/10/2019
GPNX
NOTIFICATION PROCESSED BY IB
26/10/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/10/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
09/10/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/10/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
19/09/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/09/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/09/2019
ALIE
ASSIGNED TO LIE
17/09/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/09/2019
RFNP
REFUSAL PROCESSED BY IB
09/08/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
22/07/2019
RFRR
REFUSAL PROCESSED BY MPU
22/07/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
30/06/2019
CNRT
NON-FINAL ACTION WRITTEN
29/06/2019
DOCK
ASSIGNED TO EXAMINER
26/06/2019
MAFR
APPLICATION FILING RECEIPT MAILED
25/06/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
20/06/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
13/06/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BRIGHTPLEX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.